SOCIAL CIRCLE, Ga. — Takeda Pharmaceutical Co. has earned federal approval for a second product made at its Stanton Springs facility in Walton County.
The company announced Monday morning the U.S. Food and Drug Administration approved production of Flexbumin 25%, which is indicated for burns, cardiopulmonary bypass surgery and hemolytic disease of the newborn.
“This latest approval is a significant milestone for the Georgia facility, Takeda and our patients,” Thomas Wozniewski, the company’s global manufacturing and supply officer, said in a statement.
“This new state-of-the-art facility is providing much needed additional capacity for meeting increasing global demand for plasma-derived therapies, and our team there will continue to scale up production over the coming years.”
Takeda has more than 1,000 full-time and contract employees at Stanton Springs.